2020.05.01
This is a hemostatic project that is based on European technology. It is one of the most advanced medical projects in the world. The project has completed Phase II clinical trials. MEGS is the project's exclusive representative in China(valid for one half year), and is currently helping to connect with several pharmaceutical and investment companies in China.
The Parties involved with the project will consider accepting equity investments or selling their Asian and Chinese patent rights. The project is targeting a valuation excellding $20M.
